Skip to content
OpenCapital
Get started

Immuneering Corporation IMRX Q1 2026 earnings

Reported May 15, 2026 · Before market open

Diluted EPS-$0.21Beat by $0.09
EPS estimate-$0.30

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.26

Versus estimates

Diluted EPS

Q1 2026-$0.21Beat by $0.09
Q4 2025-$0.18Beat by $0.13Q3 2025-$0.38Miss by $0.01Q2 2025-$0.40In lineQ1 2025-$0.42Miss by $0.01Q4 2024-$0.58Miss by $0.16

Ask the moment Immuneering Corporation reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immuneering Corporation report Q1 2026 earnings?
Immuneering Corporation (IMRX) reported Q1 2026 earnings on May 15, 2026 before market open.
What were Immuneering Corporation's Q1 2026 revenue and EPS?
Immuneering Corporation reported diluted EPS of $-0.21 for Q1 2026.
Did Immuneering Corporation beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.30 by $0.09.
How did Immuneering Corporation's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 50.0% from $-0.42.
Where can I find Immuneering Corporation's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001790340-26-000055) and the 10-Q periodic report (0001790340-26-000057) directly on SEC EDGAR. The filing index links above go to sec.gov.